Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ask patients, not devices, about impact of PAD

Key clinical point: Direct assessment from patients is the best measure of the impact of PAD on patients’ symptoms, functional capacity, and quality of life.

Major finding: ABI explained only 0.1%-2.1% of the variation in Peripheral Artery Questionnaire scores.

Study details: PORTRAIT studied 1,251 patients with intermittent claudication enrolled 16 sites.

Disclosures: Several authors reported serving as consultant for and/or receiving grants from various device and pharmaceutical companies involved with PAD. The senior author owns the copyright to the Peripheral Artery Questionnaire that formed the basis for the study.


Johnston A et al. J Vasc Surg. 2018;69(3):906-12.